Bliss Gvs Pharma Limited (IN:BLISSGVS)
:BLISSGVS
Want to see IN:BLISSGVS full AI Analyst Report?
BLISSGVS Stock Chart & Stats
₹144.75
-₹6.85(-3.92%)
At close: 4:00 PM EST
₹144.75
-₹6.85(-3.92%)
Day’s Range― - ―
52-Week Range₹118.35 - ₹462.70
Previous CloseN/A
Volume571.01K
Average Volume (3M)104.36K
Market Cap
₹46.52B
Enterprise Value₹47.67B
Total Cash (Recent Filing)₹2.01B
Total Debt (Recent Filing)₹524.91M
Price to Earnings (P/E)38.1
Beta1.23
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)10.40
Shares Outstanding105,788,970
10 Day Avg. Volume77,644
30 Day Avg. Volume104,358
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)2.03
Price to Sales (P/S)2.61
P/FCF Ratio29.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow and declining debt alongside rising equity/assets gives the company durable financial flexibility. This conservative capital structure reduces refinancing risk, supports steady investment or working-capital needs, and improves resilience to industry shocks over the next 2–6 months.
Consistent Revenue GrowthMid-to-high single-digit organic revenue growth with a recent uptick in net income indicates a stable demand base and improving operational performance. This steadier top-line supports recurring cash generation and reinvestment capacity, underpinning sustainable business momentum.
Diversified Formulation & Manufacturing ModelA business mix of domestic branded sales, export B2B supply and contract/loan-license manufacturing spreads revenue risk across channels and geographies. Specialty focus (women’s health) plus manufacturing capabilities provide repeatable demand and margin support versus single-channel peers.
Bears Say
Margin VolatilityHistorical swings in margins and a pronounced weak-profit year show the company’s earnings power can vary materially. Persistent margin volatility undermines predictability of profits and free cash flow and increases execution risk for medium-term planning and investment.
Choppy Cash ConversionIrregular operating and free cash flows—including episodes of negative FCF—signal working-capital or spending variability. Unpredictable cash conversion can force reliance on external funding for growth or capex and limits the company’s ability to consistently fund dividends or strategic initiatives.
Operating Profit ClarityAn atypical EBITDA-versus-EBIT relationship suggests significant non-cash or non-recurring adjustments that obscure true operating performance. This opacity complicates margin sustainability assessment and reduces comparability to peers, raising forecasting and valuation uncertainty.
Bliss Gvs Pharma Limited News
BLISSGVS FAQ
What was Bliss Gvs Pharma Limited’s price range in the past 12 months?
Bliss Gvs Pharma Limited lowest stock price was ₹118.35 and its highest was ₹462.70 in the past 12 months.
What is Bliss Gvs Pharma Limited’s market cap?
Bliss Gvs Pharma Limited’s market cap is ₹46.52B.
When is Bliss Gvs Pharma Limited’s upcoming earnings report date?
Bliss Gvs Pharma Limited’s upcoming earnings report date is Aug 04, 2026 which is in 48 days.
How were Bliss Gvs Pharma Limited’s earnings last quarter?
Currently, no data Available
Is Bliss Gvs Pharma Limited overvalued?
According to Wall Street analysts Bliss Gvs Pharma Limited’s price is currently Overvalued.
Does Bliss Gvs Pharma Limited pay dividends?
Bliss Gvs Pharma Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.28%. See more information on Bliss Gvs Pharma Limited dividends here
What is Bliss Gvs Pharma Limited’s EPS estimate?
Bliss Gvs Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bliss Gvs Pharma Limited have?
Bliss Gvs Pharma Limited has 105,788,970 shares outstanding.
What happened to Bliss Gvs Pharma Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bliss Gvs Pharma Limited?
Currently, no hedge funds are holding shares in IN:BLISSGVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bliss Gvs Pharma Limited
Established in 1984 and headquartered in Mumbai, India, Bliss GVS Pharma Limited specializes in the development, manufacturing, and distribution of a comprehensive array of pharmaceutical products. The company's pharmaceutical portfolio includes an extensive range of dosage forms, such as oral solids (tablets, capsules), various liquid and injectable preparations, topical applications (creams, gels), and advanced drug delivery systems like transdermal patches. Beyond conventional medicines, Bliss GVS also offers a diverse selection of other healthcare and personal care items, including balms, lotions, shampoos, and over-the-counter remedies. Their therapeutic focus is equally broad, encompassing solutions for anti-infectives, pain management, gastrointestinal issues, anti-malarials, dermatological conditions, nutritional support, and a wide variety of other wellness and hygiene products, including medicated and cosmetic soaps. The company actively engages in international exports, extending its market presence beyond India.
Technical Analysis
Bajaj Healthcare Ltd
―
Hester Biosciences Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Syncom Formulation (India) Ltd.
―
Windlas Biotech Ltd.
―